Use of a large patient database to analyze disease burden and treatment patterns among patients with vitiligo
Br J Dermatol. 2024 Apr 16:ljae166. doi: 10.1093/bjd/ljae166. Online ahead of print.NO ABSTRACTPMID:38623690 | DOI:10.1093/bjd/ljae166 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 16, 2024 Category: Dermatology Authors: Valeria Brazzelli Andrea Michelerio Source Type: research
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
AbstractTopical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials, significantly more ruxolitinib cream recipients were able to achieve statistically significant and clinically meaningful facial and total body repigmentation, as well as reductions in vitiligo noticea bility, compared with vehicle recipients. Efficacy was sustained in longer-term analyses to week 104 of treatment. Ruxolitinib 1.5% cream was generally tolerabl...
Source: Drugs - April 16, 2024 Category: Drugs & Pharmacology Source Type: research
A case of multiple autoimmune syndrome comprising autoimmune thyroid disease, vitiligo, morphea, and lichen sclerosus
We report a unique case of a 55-year-old female patient that presented with four autoimmune diseases: autoimmune thyroid disease, vitiligo, morphea, and lichen sclerosus. She was evaluated for progression of morphea and lichen sclerosus, and we confirmed histopathological overlapping of these two diseases in the same lesion. We discuss the increasing prevalence of autoimmune diseases and similar case reports on dermatological polyautoimmunity.PMID:38606648 (Source: Acta Dermatovenerologica Alpina, Panonica, et Adriatica)
Source: Acta Dermatovenerologica Alpina, Panonica, et Adriatica - April 12, 2024 Category: Dermatology Authors: Hana Ga šper Vesna Breznik Source Type: research
